EQS Newswire is a major provider of regulatory and corporate news. It mainly serves companies, investors and media worldwide. Through its services, EQS Newswire enables efficient and secure communication between companies and their stakeholders. Its main services include the distribution of ad hoc announcements, corporate news and the publication of financial reports that meet strict international standards.
Fri, 25.02.2022
Cassiopea S.p.A.
/ Key word(s): Delisting
Cassiopea SpA announces approval of delisting of its shares on SIX Swiss Exchange
25.02.2022 / 07:00
Lainate, Italy - February 25, 2022: Cassiopea S.p.A. (SIX: SKIN), ('Cassiopea'), a specialty pharmaceutical company developing and preparing to commercialize prescription drugs with novel...
Ad hoc announcement pursuant to Art. 53 LR
Lainate, Italy, February 4, 2022: Cassiopea S.p.A. (SIX: SKIN) ('Cassiopea') today announced that it has filed for delisting of its registered shares from SIX Swiss Exchange ('SIX'). Cassiopea has applied for a last trading day on March 4, 2022, which is subject to the approval by SIX.
About Cassiopea
Cas...
Cassiopea S.p.A.
/ Key word(s): Miscellaneous
Cassiopea SpA announces preparing delisting of shares on SIX Swiss Exchange
20.01.2022 / 07:00
Lainate, Italy - January 20, 2022: Cassiopea SpA (SIX: SKIN), a specialty pharmaceutical company developing and preparing to commercialize prescription drugs with novel mechanisms of action...
Ad hoc announcement pursuant to Art. 53 LR
Dublin, Ireland and Lainate, Italy - 17 December 2021 - Cosmo Pharmaceuticals N.V. (SIX: COPN) ("Cosmo") and Cassiopea S.p.A. (SIX: SKIN) ("Cassiopea") announce the settlement of the public exchange offer by Cosmo in accordance with articles 125 et seq. of the Federal Act on Financial Markets Infrastructur...
Ad hoc announcement pursuant to Art. 53 LR
Dublin, Ireland and Lainate, Italy - 7 December 2021 - Cosmo Pharmaceuticals N.V. (SIX: COPN) ("Cosmo") and Cassiopea S.p.A. (SIX: SKIN) ("Cassiopea") today announced the definitive final results for the public exchange offer by Cosmo in accordance with articles 125 et seq. of the Federal Act on Financial ...
Ad hoc announcement pursuant to Art. 53 LR
Dublin, Ireland and Lainate, Italy - 3 December 2021 - Cosmo Pharmaceuticals N.V. (SIX: COPN) ("Cosmo") and Cassiopea S.p.A. (SIX: SKIN) ("Cassiopea") today announced the provisional final results for the public exchange offer by Cosmo in accordance with articles 125 et seq. of the Federal Act on Financial...
About Cosmo Pharmaceuticals
Cosmo is a specialty pharmaceutical company focused on developing and commercialising products to treat selected gastrointestinal disorders and improve endoscopy quality measures through aiding the detection of colonic lesions. Cosmo has also developed medical devices for endoscopy and has a partnership with Medtronic f...
Ad hoc announcement pursuant to Art. 53 LR
Dublin, Ireland and Lainate, Italy - 16 November 2021 - Cosmo Pharmaceuticals N.V. (SIX: COPN) ("Cosmo") and Cassiopea S.p.A. (SIX: SKIN) ("Cassiopea") announced today that during the offer period of the public exchange offer in Switzerland for Cosmo to acquire all of the publicly held registered shares of...
Ad hoc announcement pursuant to Art. 53 LR
Dublin, Ireland and Lainate, Italy - 4 October 2021 - Today, Cosmo Pharmaceuticals N.V. launches a public exchange offer under Swiss takeover rules to fully acquire and delist Cassiopea S.p.A. The exchange ratio follows current market prices.
Further information is available on https://www.cosmopharma.co...
You have pressed the "". We would like to inform you that you are now leaving the information service of the portal site ayondo.com. You will be redirected to . After confirming the "Continue" button, you confirm that you have been informed of this. You also confirm that you are carrying out this process of your own free will and that it is not the result of any promotional activity or other influence. Continue to .